Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
Background<p>The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of fi...
Zapisane w:
| 1. autor: | |
|---|---|
| Kolejni autorzy: | |
| Wydane: |
2025
|
| Hasła przedmiotowe: | |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| _version_ | 1849927624394014720 |
|---|---|
| author | Xiaohu Jin (9618675) |
| author2 | Zhifeng Li (1776799) |
| author2_role | author |
| author_facet | Xiaohu Jin (9618675) Zhifeng Li (1776799) |
| author_role | author |
| dc.creator.none.fl_str_mv | Xiaohu Jin (9618675) Zhifeng Li (1776799) |
| dc.date.none.fl_str_mv | 2025-11-26T05:15:04Z |
| dc.identifier.none.fl_str_mv | 10.3389/fphar.2025.1700291.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_file_1_Cost-effectiveness_analysis_of_first-line_versus_second-line_use_of_CDK4_6_inhibitors_combined_with_endocrine_therapy_in_advanced_HR_HER2-_breast_cancer_in_China_based_on_the_SONIA_trial_docx/30717722 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Pharmacology cost-effectiveness analysis CDK4/6 inhibitors endocrine therapy HR+/HER2- breast cancer SONIA |
| dc.title.none.fl_str_mv | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | Background<p>The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of first-line versus second-line CDK4/6 inhibitor use based on the SONIA trial.</p>Methods<p>A partitioned survival model was developed to compare costs and effectiveness of first-line (CDK4/6i-first) versus second-line (CDK4/6i-second) CDK4/6 inhibitor strategies among Chinese women with advanced HR+/HER2- breast cancer. Model inputs were derived from the SONIA trial and Chinese healthcare data. Outcomes included total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Both deterministic and probabilistic sensitivity analyses were performed. Scenario analyses incorporated generic drug pricing.</p>Results<p>The base-case analysis showed that the CDK4/6i-first strategy yielded 3.07 QALYs at a lifetime cost of CNY 372420.21, compared to 2.86 QALYs and CNY 366445.93 for the CDK4/6i-second strategy. The ICER for first-line CDK4/6 inhibitor use was CNY 28126.33 per QALY, well below the willingness-to-pay (WTP) threshold of CNY 287,247/QALY. Scenario analysis with generics showed an ICER of CNY 198439.62 per QALY. Sensitivity analyses confirmed the robustness of these results.</p>Conclusion<p>This study supports the early use of CDK4/6 inhibitors combined with endocrine therapy as a cost-effective strategy for advanced HR+/HER2- breast cancer in China. Continued real-world monitoring is needed to adapt to changes in drug pricing and clinical practice.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_742cae03a2a65ef9f03bdef5929eb881 |
| identifier_str_mv | 10.3389/fphar.2025.1700291.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30717722 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docxXiaohu Jin (9618675)Zhifeng Li (1776799)Pharmacologycost-effectiveness analysisCDK4/6 inhibitorsendocrine therapyHR+/HER2- breast cancerSONIABackground<p>The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly in resource-limited settings such as China. This study evaluated the cost-effectiveness of first-line versus second-line CDK4/6 inhibitor use based on the SONIA trial.</p>Methods<p>A partitioned survival model was developed to compare costs and effectiveness of first-line (CDK4/6i-first) versus second-line (CDK4/6i-second) CDK4/6 inhibitor strategies among Chinese women with advanced HR+/HER2- breast cancer. Model inputs were derived from the SONIA trial and Chinese healthcare data. Outcomes included total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Both deterministic and probabilistic sensitivity analyses were performed. Scenario analyses incorporated generic drug pricing.</p>Results<p>The base-case analysis showed that the CDK4/6i-first strategy yielded 3.07 QALYs at a lifetime cost of CNY 372420.21, compared to 2.86 QALYs and CNY 366445.93 for the CDK4/6i-second strategy. The ICER for first-line CDK4/6 inhibitor use was CNY 28126.33 per QALY, well below the willingness-to-pay (WTP) threshold of CNY 287,247/QALY. Scenario analysis with generics showed an ICER of CNY 198439.62 per QALY. Sensitivity analyses confirmed the robustness of these results.</p>Conclusion<p>This study supports the early use of CDK4/6 inhibitors combined with endocrine therapy as a cost-effective strategy for advanced HR+/HER2- breast cancer in China. Continued real-world monitoring is needed to adapt to changes in drug pricing and clinical practice.</p>2025-11-26T05:15:04ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fphar.2025.1700291.s001https://figshare.com/articles/dataset/Supplementary_file_1_Cost-effectiveness_analysis_of_first-line_versus_second-line_use_of_CDK4_6_inhibitors_combined_with_endocrine_therapy_in_advanced_HR_HER2-_breast_cancer_in_China_based_on_the_SONIA_trial_docx/30717722CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307177222025-11-26T05:15:04Z |
| spellingShingle | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx Xiaohu Jin (9618675) Pharmacology cost-effectiveness analysis CDK4/6 inhibitors endocrine therapy HR+/HER2- breast cancer SONIA |
| status_str | publishedVersion |
| title | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| title_full | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| title_fullStr | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| title_full_unstemmed | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| title_short | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| title_sort | Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx |
| topic | Pharmacology cost-effectiveness analysis CDK4/6 inhibitors endocrine therapy HR+/HER2- breast cancer SONIA |